Cardiovascular Center, Nagoya Daini Red Cross Hospital, Aichi, Japan.
Department of Nuclear Medicine, Kanazawa University Hospital, Ishikawa, Japan.
J Cardiol. 2014 Feb;63(2):159-64. doi: 10.1016/j.jjcc.2013.07.006. Epub 2013 Sep 4.
The findings of our recent study entitled, "Japanese Assessment of Cardiac Events and Survival Study by Quantitative Gated SPECT (J-ACCESS)" showed that myocardial perfusion single photon emission computed tomography (MPS) can detect coronary artery disease (CAD) and help to predict future cardiac events in patients with suspected or extant CAD. However, the extent of the benefit conferred by percutaneous coronary intervention (PCI) as an initial management strategy compared with optimal medical therapy remains controversial. Little evidence supports the notion that myocardial ischemia identified using MPS is an alternative target of coronary revascularization to reduce the likelihood of developing cardiac events.
The multicenter, prospective cohort J-ACCESS 4 study aims to clarify the prognostic impact of reducing myocardial ischemia determined using electrocardiogram-gated MPS in Japanese patients with coronary artery disease. We started to register patients in J-ACCESS 4 at 74 facilities during June 2012 and will continue to do so until December 2013 or until the cohort comprises 500 patients who will participate in the study from one month before, until two months after stress/rest MPS assessment. Imaging data, the background of the patients including coronary risk factors and treatment before MPS assessments will be analyzed. The patients will undergo coronary revascularization within two months after MPS and/or receive appropriate medical therapy. The second stress/rest MPS will be performed from 4 to 10 months after coronary revascularization or registration. They will be followed up for over one year after the second MPS assessment. The primary endpoints will be cardiac death, sudden death of unknown cause, non-fatal myocardial infarction, and hospitalization for heart failure. The secondary endpoints will comprise death due to all causes including non-cardiac death and any cardiovascular events. This study will be completed in 2015. Here, we describe the design of the J-ACCESS 4 study.
我们最近的一项名为“日本定量门控单光子发射计算机断层扫描心肌灌注评估冠心病及生存研究(J-ACCESS)”的研究结果表明,单光子发射计算机断层扫描心肌灌注(MPS)可检测冠心病(CAD)并有助于预测疑似或存在 CAD 患者的未来心脏事件。然而,经皮冠状动脉介入治疗(PCI)作为初始治疗策略与最佳药物治疗相比所带来的获益程度仍存在争议。几乎没有证据支持这样一种观点,即使用 MPS 确定的心肌缺血是冠状动脉血运重建以降低发生心脏事件可能性的替代靶标。
这项多中心前瞻性队列 J-ACCESS 4 研究旨在阐明在日本 CAD 患者中使用心电图门控 MPS 确定的心肌缺血减少对预后的影响。我们于 2012 年 6 月在 74 个中心开始招募 J-ACCESS 4 患者,并将继续招募,直到 2013 年 12 月或直到队列纳入 500 例患者。这些患者将在进行 MPS 评估前一个月至评估后两个月内参与研究。将分析患者的影像数据、包括冠心病危险因素和 MPS 评估前治疗情况在内的患者背景。患者将在 MPS 后两个月内接受冠状动脉血运重建和/或接受适当的药物治疗。在冠状动脉血运重建或登记后 4 至 10 个月将进行第二次 MPS。在第二次 MPS 评估后一年以上将对患者进行随访。主要终点是心脏性死亡、原因不明的猝死、非致死性心肌梗死和心力衰竭住院。次要终点包括全因死亡(包括非心源性死亡)和任何心血管事件。本研究将于 2015 年完成。此处我们介绍 J-ACCESS 4 研究的设计。